Skip to main content
Journal cover image

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

Publication ,  Journal Article
Josse, RG; Majumdar, SR; Zheng, Y; Adler, A; Bethel, MA; Buse, JB; Green, JB; Kaufman, KD; Rodbard, HW; Tankova, T; Westerhout, CM; Holman, RR ...
Published in: Diabetes Obes Metab
January 2017

AIM: To examine fracture incidence among participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). RESEARCH DESIGN AND METHODS: We used data from 14 671 participants in the TECOS study who were randomized double-blind to sitagliptin (n = 7332) or placebo (n = 7339). Cumulative fracture incidence rates were calculated and their association with study treatment assignment was examined using multivariable Cox proportional hazards regression. RESULTS: The baseline mean (standard deviation) participant age was 65.5 (8.0) years, diabetes duration was 11.6 (8.1) years and glycated haemoglobin level was 7.2 (0.5)% [55.2 (5.5) mmol/mol], and 29.3% of participants were women and 32.1% were non-white. During 43 222 person-years' follow-up, 375 (2.6%; 8.7 per 1000 person-years) had a fracture; 146 were major osteoporotic fractures (hip, n = 34; upper extremity, n = 81; and clinical spine, n = 31). Adjusted analyses showed fracture risk increased independently with older age (P < .001), female sex (P < .001), white race (P < .001), lower diastolic blood pressure (P < .001) and diabetic neuropathy (P = .003). Sitagliptin, compared with placebo, was not associated with a higher fracture risk [189 vs 186 incident fractures: unadjusted hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.82 to 1.23, P = .944; adjusted HR 1.03, P = .745], major osteoporotic fractures (P = .673) or hip fractures (P = .761). Insulin therapy was associated with a higher fracture risk (HR 1.40, 95% CI 1.02-1.91; P = .035), and metformin with a lower risk (HR 0.76, 95% CI 0.59-0.98; P = .035). CONCLUSION: Fractures were common among people with diabetes in the TECOS study, but were not related to sitagliptin therapy. Insulin and metformin treatment were associated with higher and lower fracture risks, respectively.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

January 2017

Volume

19

Issue

1

Start / End Page

78 / 86

Location

England

Related Subject Headings

  • White People
  • Sitagliptin Phosphate
  • Sex Factors
  • Risk Factors
  • Proportional Hazards Models
  • Osteoporotic Fractures
  • Middle Aged
  • Metformin
  • Male
  • Insulin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Josse, R. G., Majumdar, S. R., Zheng, Y., Adler, A., Bethel, M. A., Buse, J. B., … TECOS Study Group, . (2017). Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. Diabetes Obes Metab, 19(1), 78–86. https://doi.org/10.1111/dom.12786
Josse, Robert G., Sumit R. Majumdar, Yinggan Zheng, Amanda Adler, M Angelyn Bethel, John B. Buse, Jennifer B. Green, et al. “Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.Diabetes Obes Metab 19, no. 1 (January 2017): 78–86. https://doi.org/10.1111/dom.12786.
Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, et al. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. Diabetes Obes Metab. 2017 Jan;19(1):78–86.
Josse, Robert G., et al. “Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.Diabetes Obes Metab, vol. 19, no. 1, Jan. 2017, pp. 78–86. Pubmed, doi:10.1111/dom.12786.
Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW, TECOS Study Group. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. Diabetes Obes Metab. 2017 Jan;19(1):78–86.
Journal cover image

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

January 2017

Volume

19

Issue

1

Start / End Page

78 / 86

Location

England

Related Subject Headings

  • White People
  • Sitagliptin Phosphate
  • Sex Factors
  • Risk Factors
  • Proportional Hazards Models
  • Osteoporotic Fractures
  • Middle Aged
  • Metformin
  • Male
  • Insulin